Utilidad del tratamiento con quelantes de hierro en niños politransfundidos con diagnóstico de anemia de células falciformes atendidos en el Hospital Roberto Gilbert enero 2013 - enero 2018.

Abstract

Introduction: Sickle cell anemia is a genetic pathology of hemoglobin that appears in 2.2 out of every 1000 births worldwide (16). It is characterized by an accelerated destruction of erythrocytes that leads to the appearance of anemia, which may require multiple blood transfusions that cause adverse effects such as iron overload. (18) Iron chelators are the treatment of choice. (8) Materials and methods: It was performed a Descriptive, Observational, Retrospective study of Longitudinal cut in a period of 5 years in 96 pediatric patients. Results: To evaluate the usefulness of iron chelating therapy in polytransfused children with sickle cell anemia, 96 pediatric patients whose mean age was 10 years were analyzed; with a predominance of women 52.08%, when comparing the mean ferritin before and after chelating therapy, significant differences were observed with p-value <0.001, where the means were 2983.38 ng / mL before therapy vs 2018 , 47 ng / mL after therapy; the effect size in the test was r = 0.63, which is considered large, that is, there is high evidence of the relationship between chelator therapy and changes in ferritin values in pediatric patients with sickle cell anemia. Conclusions: Iron chelators have great utility, efficacy and safety in the management of iron overload since they significantly decrease serum ferritin levels in polytransfused patients diagnosed with sickle cell anemia.